Phase 1 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a confirmed diagnosis of multiple myeloma.
• People whose multiple myeloma has come back or stopped responding to 3 or more previous treatments, where those treatments included at least one drug from each of these three groups: immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibody therapies — and for whom other standard treatments are not suitable or have caused intolerable side effects.
• People whose blood counts, kidney function, liver function, and heart function are at adequate levels as determined by the trial site.

Who may not be able to join:

• People who have been diagnosed with a related but different condition, such as MGUS (monoclonal gammopathy of undetermined significance), smoldering myeloma, Waldenström's macroglobulinemia, or IgM myeloma.
• People who have active plasma cell leukemia (a more aggressive form of blood cancer related to myeloma).
• People who have a rare condition called POEMS syndrome, which involves nerve damage, enlarged organs, hormone problems, and skin changes alongside abnormal proteins in the blood.
• People who have previously experienced Stevens-Johnson syndrome (a serious skin and mucous membrane reaction).
• People who have had localised radiation therapy to a disease site within the 2 weeks before the first dose of the study drug.
• People who had their own stem cells or bone marrow transplanted back into them (autologous transplant) less than 90 days before the first dose of the study drug.
• People who received a stem cell or solid organ transplant from a donor (allogeneic transplant) within the past 12 months, or who are currently taking medications to suppress the immune system due to graft-versus-host disease.
• People who have received chemotherapy, targeted cancer therapy, or radiation therapy within the 2 weeks before the first dose of the study drug.
• People currently taking high-dose corticosteroids (steroid medications), unless those steroids are being taken for a condition unrelated to myeloma.
• People whose multiple myeloma has spread to the central nervous system (the brain or spinal cord).
• People who have another active cancer, with certain exceptions — including adequately treated skin cancers or early-stage cervical cancer; a Stage 1 cancer that has been in full remission for 2 or more years; low-risk prostate cancer meeting specific criteria (confirm with trial site); or any other cancer from which the person has been cancer-free for 3 or more years.
• People who have an active serious infection that requires intravenous (IV) antibiotic or antifungal treatment.
• People whose Type 2 diabetes is poorly controlled.

Important: Always verify eligibility with the trial site directly before applying.